JP2005532256A - 慢性関節リウマチを治療するためのｌｉｒ機能の調節 - Google Patents

慢性関節リウマチを治療するためのｌｉｒ機能の調節 Download PDF

Info

Publication number
JP2005532256A
JP2005532256A JP2003543537A JP2003543537A JP2005532256A JP 2005532256 A JP2005532256 A JP 2005532256A JP 2003543537 A JP2003543537 A JP 2003543537A JP 2003543537 A JP2003543537 A JP 2003543537A JP 2005532256 A JP2005532256 A JP 2005532256A
Authority
JP
Japan
Prior art keywords
lir
patient
cells
antibody
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003543537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532256A5 (enExample
Inventor
アーム，ジヨナサン・ピー
テドラ，ニコデムス
ボルゲス，ルイス・ジエー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005532256A publication Critical patent/JP2005532256A/ja
Publication of JP2005532256A5 publication Critical patent/JP2005532256A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2003543537A 2001-11-14 2002-11-12 慢性関節リウマチを治療するためのｌｉｒ機能の調節 Pending JP2005532256A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33589901P 2001-11-14 2001-11-14
PCT/US2002/036372 WO2003041650A2 (en) 2001-11-14 2002-11-12 Modulation of lir function to treat rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2005532256A true JP2005532256A (ja) 2005-10-27
JP2005532256A5 JP2005532256A5 (enExample) 2006-01-12

Family

ID=30770813

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543537A Pending JP2005532256A (ja) 2001-11-14 2002-11-12 慢性関節リウマチを治療するためのｌｉｒ機能の調節

Country Status (8)

Country Link
US (1) US20050238643A1 (enExample)
EP (1) EP1453540A4 (enExample)
JP (1) JP2005532256A (enExample)
AU (1) AU2002360376B2 (enExample)
CA (1) CA2466118A1 (enExample)
MX (1) MXPA04004491A (enExample)
PL (1) PL374463A1 (enExample)
WO (1) WO2003041650A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101192A1 (ja) * 2009-03-03 2010-09-10 国立大学法人九州大学 関節リウマチまたはその関連疾患の予防または治療剤
JP2013517331A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
JP2015537009A (ja) * 2012-11-20 2015-12-24 リバイブ・セラピューティクス・インコーポレイテッド 痛風の治療におけるブシラミンの使用
JP2023515398A (ja) * 2020-02-12 2023-04-13 バイオインベント インターナショナル アクティエボラーグ Ｌｉｌｒｂ３抗体分子およびその使用

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006049215A1 (ja) * 2004-11-02 2006-05-11 Dainippon Sumitomo Pharma Co., Ltd. 自己免疫疾患を治療するための併用薬
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
CA2611519A1 (en) 2005-06-17 2006-12-28 Tolerx, Inc. Ilt3 binding molecules and uses therefor
WO2008094176A2 (en) 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
CN102089327A (zh) * 2008-05-13 2011-06-08 健泰科生物技术公司 抗PirB抗体
CA2787783A1 (en) * 2010-01-20 2011-07-28 Tolerx, Inc. Anti-ilt5 antibodies and ilt5-binding antibody fragments
TWI796329B (zh) 2017-04-07 2023-03-21 美商默沙東有限責任公司 抗－ilt4抗體及抗原結合片段
JP7391868B2 (ja) 2017-12-22 2023-12-05 ジョウンセ セラピューティクス， インク． Ｌｉｌｒｂ２に対する抗体
AU2019302454A1 (en) 2018-07-09 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to ILT4
IL297748A (en) 2020-05-01 2022-12-01 Ngm Biopharmaceuticals Inc ilt binding agents and methods of using them

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2278154A1 (en) * 1997-01-21 1998-07-23 Human Genome Sciences, Inc. Fc receptors and polypeptides
US6448035B1 (en) * 1997-04-24 2002-09-10 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR)
US6384203B1 (en) * 1999-05-12 2002-05-07 Immunex Corporation Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)
CA2398251A1 (en) * 2000-01-25 2001-08-02 Hyseq, Inc. Methods and materials relating to leukocyte immunoglobulin receptor-like (lir-like) polypeptides and polynucleotides

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101192A1 (ja) * 2009-03-03 2010-09-10 国立大学法人九州大学 関節リウマチまたはその関連疾患の予防または治療剤
JP5637981B2 (ja) * 2009-03-03 2014-12-10 国立大学法人北海道大学 関節リウマチまたはその関連疾患の予防または治療剤
JP2013517331A (ja) * 2010-01-20 2013-05-16 トーラックス インコーポレイテッド 抗ｉｌｔ５抗体およびｉｌｔ５結合抗体断片による免疫調節
JP2015537009A (ja) * 2012-11-20 2015-12-24 リバイブ・セラピューティクス・インコーポレイテッド 痛風の治療におけるブシラミンの使用
JP2023515398A (ja) * 2020-02-12 2023-04-13 バイオインベント インターナショナル アクティエボラーグ Ｌｉｌｒｂ３抗体分子およびその使用

Also Published As

Publication number Publication date
MXPA04004491A (es) 2005-05-16
EP1453540A4 (en) 2005-06-01
US20050238643A1 (en) 2005-10-27
WO2003041650A2 (en) 2003-05-22
WO2003041650A3 (en) 2004-01-29
PL374463A1 (en) 2005-10-17
AU2002360376B2 (en) 2006-05-18
EP1453540A2 (en) 2004-09-08
CA2466118A1 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
US20200095305A1 (en) Methods of modulating immune responses using bcma polypeptide
DE69933115T2 (de) Verwendung eines antagonisten antikörpers gegen den entzündungsmediator oncostatin m (osm)
US6210669B1 (en) Methods and compositions for immunomodulation
US6376459B1 (en) Inhibiting B cell activation with soluble CD40 or fusion proteins thereof
AU705114B2 (en) Fas antagonists and uses thereof
EP2295079A2 (en) Method for treating inflammation
JP2005536511A (ja) ４−１ｂｂ結合物質を用いる治療及び予防
JP2005532256A (ja) 慢性関節リウマチを治療するためのｌｉｒ機能の調節
US5942229A (en) Method for prolonged suppression of humoral immune response to a thymus-dependent antigen therapeutic agent
AU2016227322A1 (en) Dual signaling protein (DSP) fusion proteins, and methods of using thereof for treating diseases
AU2002360376A1 (en) Modulation of LIR function to treat rheumatoid arthritis
US6015559A (en) Fas antagonists
AU2009321740B2 (en) IL-3 inhibitors in use for treatment of rheumatoid arthritis in an early stage
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
US20030021785A1 (en) Use of rank antagonists to treat cancer
CN114901313A (zh) 急性期的视神经脊髓炎的预防或治疗剂
JP2002510643A (ja) 狼瘡およびその関連腎臓疾患の治療および／または後退のための抗−ｇｐ３９抗体の使用
HK1157388A (en) Baff receptor (bcma), an immunoregulatory agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090714